This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Hypersensitivity  • Diagnosis  • Psoriasis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Lidian L. A. Lecluse, MD; Gamze Piskin, MD, PhD; Jan D. Bos, MD, PhD, FRCP

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With great interest, we read the article by Seneschal et al¹ describing 8 patients who experienced psoriasiform eruptions during anti–tumor necrosis factor therapy. These patients were patch tested with the European standard series and 2 anti–tumor necrosis factor molecules. One patient who had developed adalimumab-related psoriasiform plaques responded to the etanercept patch test with edema and vesicles after 48 hours. Day 8 readings showed a flare of dermatitis in half the patients.^1-2

Positive patch test results to biologic agents have also been described previously.³ A flare-up of the cutaneous eruption occurred in one patient, and nausea and malaise developed in another, who had experienced a similar reaction after infliximab administration. The authors theorized that infliximab is well absorbed percutaneously, since cutaneous application caused adverse events.

Patch tests with suspected compounds are sometimes helpful in determining . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Psoriasiform Eruptions During Anti–TNF- Treatment: Psoriasis or Not?
Julien Seneschal, Sébastien Lepreux, Brigitte Milpied, Thierry Schaeverbeke, and Alain Taïeb
Arch Dermatol. 2007;143(12):1593-1595.
EXTRACT | FULL TEXT  

The Use of Patch Tests in Determining Hypersensitivity to Etanercept and Infliximab—Reply
Julien Seneschal, Brigitte Milpied, and Alain Taïeb
Arch Dermatol. 2008;144(8):1071-1072.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Cutaneous Drug Eruption to Infliximab: Report of 4 Cases With an Interface Dermatitis Pattern
Gloria Vergara, Juan Francisco Silvestre, Isabel Betlloch, Paloma Vela, María Pilar Albares, and José Carlos Pascual
Arch Dermatol. 2002;138(9):1258-1259.
EXTRACT | FULL TEXT